Beth L. Laube

TL;DR: A collaboration of multidisciplinary experts on the delivery of pharmaceutical aerosols was facilitated by the European Respiratory Society and the International Society for Aerosols in Medicine to draw up a consensus statement with clear, up-to-date recommendations that enable the pulmonary physician to choose the type of aerosol delivery device that is most suitable for their patient.

TL;DR: It is demonstrated that bronchoprotection is a potent physiologic function of lung inflation and established its absence, even in mild asthma.

TL;DR: This international task force report updates general considerations for bronchial challenge testing and the performance of the methacholine challenge test to include notable changes from prior recommendations in order to accommodate newer delivery devices.

TL;DR: The continued expansion of the role of aerosol therapy will probably depend on demonstration of the safety of this route of administration for drugs that have their targets outside the lung and are administered long term, on the development of new drugs and drug carriers that can efficiently target hard-to-reach cell populations within the lungs of patients with disease, and on the developed of devices that improve aerosol delivery to infants.

TL;DR: In this article, a rigid housing for inhaling pharmaceutical aerosols is described, where the patient is aided by having the initial velocity of the aerosolized medicine reduced to zero by virtue of the initial delivery of the same to the housing interior, and by maintaining the volumetric flow rate of the inhaled medication maintained below required limits.